Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients

2004 ◽  
Vol 124 (4) ◽  
pp. 547-554 ◽  
Author(s):  
Nicola Conran ◽  
Camila Oresco-Santos ◽  
Heloisa C. Acosta ◽  
André Fattori ◽  
Sara T. O. Saad ◽  
...  
Blood ◽  
1980 ◽  
Vol 56 (6) ◽  
pp. 963-968 ◽  
Author(s):  
JP Piau ◽  
J Delaunay ◽  
S Fischer ◽  
M Tortolero ◽  
G Schapira

We have investigated adenylate cyclase in ghosts from normal and pathologic human red blood cells. Basic parameters such as specific activity, apparent Michaelis constant (KMapp), and response to effectors: sodium fluoride (NaF), 5′-guanylyl imidodiphosphate (Gpp (NH)p), isoproterenol, and PGE1 were investigated. Basal and NaF- stimulated activities were measured in ghosts from patients with hereditary spherocytosis, sickle cell disease, and various unidentified hemolytic anemias. Both activities were increased in any of these pathologic conditions as compared with those of normal red blood cells. Normal values were found in patients with hereditary spherocytosis after splenectomy and in patients with heterozygous sickle cell disease. There was a good correlation between the reticulocyte count and adenylate cyclase activity in hereditary spherocytosis and in sickle cell disease with reticulocyte count lower than 10%. The enzyme activity of the first group was about three times that of the second group. There was no correlation at all in sickle cell disease with higher reticulocytosis and in the group of unidentified hemolytic anemias. These results suggest that increased adenylate cyclase activities are not specific of any of these diseases. In the patients with hereditary spherocytosis, the adenylate cyclase activity seems to be essentially related to younger mean age of red blood cell population while in the patients with sickle cell disease and in others with unidentified hemolytic anemias some additional factors might interfere directly with the enzyme and alter its activity.


1997 ◽  
Vol 273 (4) ◽  
pp. H1949-H1955 ◽  
Author(s):  
Michaela Straznicka ◽  
Gary Gong ◽  
James Tse ◽  
Peter M. Scholz ◽  
Harvey R. Weiss

We tested the hypothesis that cardiac myocytes from hypertensive (one kidney, one clip; 1K,1C) cardiac-hypertrophied rabbits require higher guanosine 3′,5′-cyclic monophosphate (cGMP) to similarly lower O2consumption than control myocytes and that this effect is caused by differences in guanylate cyclase activity. Using isolated myocytes from control and 1K,1C New Zealand White rabbits, we obtained O2 consumption (nl O2 ⋅ min−1 ⋅ 105cells) and cGMP (fmol/105 cells) levels after stimulation of guanylate cyclase with nitroprusside, CO, or guanylin (10−8–10−5M). Soluble guanylate cyclase activity was also determined. Basal cGMP was elevated in 1K,1C vs. control (176 ± 28 vs. 85 ± 13) myocytes. cGMP increased in 1K,1C and control myocytes after stimulation with nitroprusside, CO, and guanylin. Guanylate cyclase activity in 1K,1C vs. control myocytes was not statistically different. Basal O2 consumption in 1K,1C vs. control myocytes was comparable (307 ± 1 vs. 299 ± 22). O2 consumption was similarly decreased when guanylate cyclase was stimulated. Control regression equations correlating cGMP and O2consumption were O2 consumption = −1.46 ⋅ [cGMP] + 444.65 ( r = 0.96) for CO, O2 consumption = −0.58 ⋅ [cGMP] + 328.48 ( r = 0.82) for nitroprusside, and O2 consumption = −1.25 ⋅ [cGMP] + 389.15 ( r = 0.88) for guanylin. The 1K,1C regression equations were O2consumption = −1.36 ⋅ [cGMP] + 537.81 ( r = 0.97) for CO, O2 consumption = −0.23 ⋅ [cGMP] + 307.30 ( r = 0.88) for nitroprusside, and O2 consumption = −1.27 ⋅ [cGMP] + 502.91 ( r = 0.89) for guanylin. These data indicate that 1K,1C hypertrophic myocytes had higher cGMP than controls at every level of O2consumption. This effect was not caused by differences in basal or maximal guanylate cyclase activity.


1981 ◽  
Vol 240 (2) ◽  
pp. E79-E82
Author(s):  
D. L. Vesely

The objective of this investigation was to determine whether physiological levels of growth hormone have part of their mechanism of action through stimulation of guanylate cyclase (EC 4.6.1.2.). Rat and human growth hormones enhanced the activity of soluble guanylate cyclase two- to fourfold in rat gracilis anticus skeletal muscle, liver, lung, heart, pancreas, and kidney cortex at a concentration of 10 nM. Dose-response relationships revealed that more than half-maximal stimulation of guanylate cyclase activity was seen at a concentration as low as 10 nM and nonstimulation of guanylate cyclase activity was seen when the concentration was decreased to 1 nM. Maximal enhancement was seen at 100 nM of growth hormone, and there was no further enhancement when the concentration was increased to the micromolar or millimolar range. Thus, the data in this investigation indicate that at concentrations at which growth hormone is known to cause its growth-promoting effects, growth hormone does cause an enhancement of the activity of the guanylate cyclase-cyclic GMP system.


Sign in / Sign up

Export Citation Format

Share Document